References
- Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)2018 Available form http://www.goldcopd.orgAccessed February 2, 2018
- Ferreira-GonzalezIPermanyer-MiraldaGBusseJWMethodologic discussions for using and interpreting composite endpoints are limited, but still identify major concernsJ Clin Epidemiol200760765165717573977
- TomlinsonGDetskyASComposite end points in randomized trials: there is no free lunchJAMA2010303326726820085955
- SinghDMaleki-YazdiMRTombsLIqbalAFahyWANayaIPrevention of clinically important deteriorations in COPD with ume-clidinium/vilanterolInt J Chron Obstruct Pulmon Dis2016111413142427445468
- SinghDD’UrzoADChuecosFMunozAGarcia GilEReduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterolRespir Res201718110628558833
- BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
- VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
- WedzichaJABanerjiDChapmanKRFLAME InvestigatorsIndacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPDN Engl J Med2016374232222223427181606
- ZhongNWangCZhouXLANTERN InvestigatorsLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
- AnzuetoARVogelmeierCFKostikasKThe effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPDInt J Chron Obstruct Pulmon Dis2017121325133728496316
- VogelmeierCFGagaMAalamian-MattheisMCRYSTAL study investigatorsEfficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trialRespir Res201718114028720132
- VestboJEdwardsLDScanlonPDECLIPSE InvestigatorsChanges in forced expiratory volume in 1 second over time in COPDN Engl J Med2011365131184119221991892
- SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med20141417825404569
- TsiligianniIGAlmaHJde JongCInvestigating sensitivity, specificity, and area under the curve of the Clinical COPD Questionnaire, COPD Assessment Test, and Modified Medical Research Council scale according to GOLD using St George’s Respiratory Questionnaire cutoff 25 (and 20) as referenceInt J Chron Obstruct Pulmon Dis2016111045105227274226
- WedzichaJABanerjiDChapmanKRIndacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPDN Engl J Med20163742222223427181606
- WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
- BeehKMBurgelPRFranssenFMEHow do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease?Am J Respir Crit Care Med2017196213914927922741
- KostikasKSiafakasNMDoes the term “Deflators” reflect more accurately the beneficial effects of long-acting bronchodilators in COPD?COPD201613553753927115572
- Maleki-YazdiMRSinghDAnzuetoATombsLFahyWANayaIAssessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three tandomized trialsAdv Ther201733122188219927796912
- NayaITombsLMullerovaHComptonCJonePLong-term outcome following first clinically important deterioration in COPDEur Respir J201648A304